Hyloris Pharmaceuticals SA HYL.BR · Stock Open Hyloris Pharmaceuticals SA in new tab
Hyloris Pharmaceuticals SA Analysis (HYL.BR)
Is Hyloris Pharmaceuticals SA a good investment? Hyloris Pharmaceuticals SA (HYL.BR) is currently trading at 4.36 EUR. Market analysts have a consensus price target of 13.20 EUR. This suggests a potential upside from current levels.
Earnings Schedule: Hyloris Pharmaceuticals SA is expected to release its next earnings report on Sept. 24, 2026. The market consensus estimate for Forward EPS is -0.23.
Investor FAQ
Does Hyloris Pharmaceuticals SA pay a dividend?
No, it does not currently pay a dividend.
What asset class is Hyloris Pharmaceuticals SA?
Hyloris Pharmaceuticals SA is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Sept. 24, 2026. The company currently has a trailing EPS of -0.24.
Company Profile
Hyloris Pharmaceuticals SA engages in the research, development, and manufacture of pharmaceutical products to address medical needs. The company offers Maxigesic IV, a combination of paracetamol and ibuprofen used for post-operative pain, the opioid crisis, and acute pain; Podofilox Gel, an antimycotic drug for the treatment of external genital and perianal warts caused by various types of the human papilloma virus; and Sotalol IV to treat atrial fibrillation. It also develops Aspirin IV and HY-074 IV to reduce the risk of morbidity and mortality associated with an emergency cardiac event, such as myocardial infarction or stroke; Milrinone ER for right heart failure due to left ventricular device; Dofetilide IV to treat atrial fibrillation; Metolazone IV for the treatment of salt and water retention, including edema accompanying congestive heart failure and renal diseases; and HY-075 IV to prevent and treat cardiovascular diseases. The company offers other value-added products comprising Tranexamic Acid Oral Rinse for preventing and treating excessive bleeding in patients on blood thinners undergoing dental procedures; Alenura to treat pain associated with interstitial cystitis/bladder pain syndrome; Miconazole/Domiphen Bromide cream to treat vaginal infections caused by candida yeast and/or bacteria, including a biofilm; PTX-252 to treat acute myeloid leukemia; Atomoxetine oral Liquid for the treatment of attention deficit hyperactivity disorder; HY-083 to treat idiopathic rhinitis; HY-088 for hypophosphatemia; HY-090 to treat burning mouth syndrome; HY-091 for vulvar lichen sclerosis; HY-095 to treat equine gastric ulcer; Pantoprazole IV to treat gastric acidity, and ulcers and erosive esophagitis; Ondansetron for nausea and vomiting; and HY-094 to treat iron deficiency. It has collaboration agreement with FHP BV, Pleco Therapeutics, Vaneltix Pharma, Inc., and AFT Pharmaceuticals. The company was incorporated in 2012 and is headquartered in Liège, Belgium.
Community Discussion